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tion of 4,531 deaths from IPD and 34,648 deaths from hospitalized pneumonia over
10 years. Compared to no vaccination, PCV13 vaccination would be cost-effective at
RM21,998 per QALY gained from the societal perspective. Compared to PCV10,
PCV13 vaccination would avoid an additional 9,651 cases of IPD, 392,684 and
980,434 cases of hospitalized and non-hospitalized pneumonia respectively, and
81,118 cases of AOM with the prevention of 18,736 deaths. Compared to PCV10,
PCV13 vaccination would be cost-effective at RM6,315 per QALY gained.
CONCLUSIONS: Universal pediatric PCV13 vaccination in Malaysia was estimated
to reduce the burden of pneumococcal diseases and is expected to be cost-effective
compared with both no vaccination and PCV10.
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OBJECTIVES: Pharmacological approaches available in chronic hepatitis B (CHB)
are based on 48-weeks finite course of peg-interferon (PEG) or continuous admin-
istration of nucleoside analogues. Recent studies gave way to early identification of
responders to PEG with a stopping rule based on virologic and serologic markers at
week 12. Objective of this study is the cost-effectiveness analysis of HBeAg-nega-
tive CHB treatment with PEG with stopping rule and switch to current most effec-
tive analogues, entecavir (ETV) or tenofovir (TDF) in Italy. METHODS: A Markov
model was developed in the states: CHB, virologic response, relapse, HBsAg clear-
ance, compensated and decompensated cirrhosis, hepatocarcinoma, liver trans-
plant, post-liver transplant and death. A systematic review of the clinical and
economic literature was performed to find appropriate information. The simulated
strategies were: 1) No treatment; 2) PEG first-line followed by switch to ETV/TDF for
patients either meeting w-12 stopping rule or not responding/relapsing after the
complete course; 3) First-line ETV/TDF in CHB before progression to compensated
cirrhosis (CC); 4) ETV/TDF treatment delayed until CC. ETV and TDF were consid-
ered alternatively for a total of 8 strategies. Outcomes were quality-adjusted life
years (QALY) and costs, calculated from the Italian NHS perspective. RESULTS: The
strategies provided 10.4, 15.3, 15.0, 12.0 QALYs, for no-treatment, PEGETV/TDF,
ETV/TDF-in-CHB and ETV/TDF-in-CC. No meaningful difference in outcomes was
found when ETV or TDF were considered. The average per-patient lifetime cost was
€27,090, €59,270, €69,050, €33,520 with no-treatment, PEGTDF, TDF-in-CHB and
TDF-in-CC. Costs using ETV were 19%-48% higher. PEGTDF was dominant with
respect to TDF-in-CHB and with an ICER of €6,590/QALY and € 7,750/QALY when
compared to no-treatment and TDF-in-CC.CONCLUSIONS:Non treatment or treat-
ment delayed until cirrhosis yielded the poorest outcomes. The strategy of a PEG
first-line with the stopping rule showed a convenient cost-effectiveness profile,
providing the optimal trade-off between clinical efficacy and costs.
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OBJECTIVES: To evaluate cost–effectiveness of pneumococcal vaccination with
10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate
vaccine (PHiD-CV) compared with 13-valent pneumococcal conjugate vaccine
(PCV-13) and no vaccination in Kazakhstan. METHODS: A steady state model with
a one-year time horizon was developed to project the impact of vaccination on the
incidence of pneumococcal and non-typeable Haemophilus influenzae infections in
children aged 0-10 years. Disease incidence rates for meningitis, bacteremia, pneu-
monia and acute otitis media (AOM) were based on data from the Ministry of
Health, benchmarked with other countries and validated by a group of local ex-
perts. Pneumococcal serotypes distribution is based on 4,752 samples reported by
GAVI for Asian region. Serotypes coverage rates of 65.67% and 69.5% for PHiD-CV
and PCV-13, payer perspective, 31 schedule, no herd protection were assumed.
RESULTS: PHiD-CV and PCV-13 are projected to prevent more cases of invasive
disease (278; 294 respectively), and pneumonia hospitalizations (12270; 12270 re-
spectively) compared to no vaccination. PHiD-CV and PCV-13 are projected to pre-
vent additional myringotomies (1920; 949 respectively) and GP visits due to AOM
(70,057; 34,639 respectively) compared to no vaccination strategy. No difference in
absolute number of death was projected when PHiD-CV is compared with PCV-13.
Vaccinating a birth cohort with PHiD-CV or PCV-13 is expected to generate 4,541
and 4,388, respectively, more QALYs compared to no vaccination. At vaccine steady
state PHiD-CV is projected to generate KZT 1.2M in direct medical cost-savings
compared with PCV-13. Sensitivity analyses indicate that incidence rate of menin-
gitis and bacteremia are the most sensitive parameters in the model.
CONCLUSIONS: Pneumococcal conjugate vaccines would be cost effective inter-
ventions for Kazakhstan. However, PHiD-CV dominates PCV-13 because it has a
larger potential QALY gain and higher cost offset related to the additional benefits
due to AOM reduction.
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OBJECTIVES: To evaluate the cost-effectiveness of palivizumab as respiratory syn-
cytial virus prophylaxis in preterm infants born at 35 weeks’ gestation or earlier,
and to determine how the cost-effectiveness of prophylaxis differs among sub-
groups according to risk factors for RSV-related hospitalization. METHODS: A de-
cision analytic model was designed to assess the cost-effectiveness of prophylaxis
with palivizumab for preterm infants born at  35 weeks’ gestational age and  6
months of age compared with no prophylaxis. And by using this model, subgroup
analyses were conducted to evaluate cost-effectiveness for children with different
risk factors related to RSV hospitalization (gestational age, age at the start of the
RSV season, with chronic lung disease, having siblings at school, discharge through
RSV season). RESULTS: The expected costs and QALYs for preterm infants with
palivizumab prophylaxis were higher than those with no prophylaxis. The incre-
mental cost-effectiveness ratio (ICER) for the preterm infants was 19,928,984 KRW
per QALY. The cost-effectiveness of palivizumab varied among the subgroups with
different risk factors. The prophylaxis with palivizumab may be cost-effective
(based on a threshold of 20,000,000 KRW per QALY) for preterm infants with one or
more risk factors according to the age at the start of the RSV season. The prophy-
laxis with palivizumab for preterm infants was cost-effective for infants under 3
months old with 1 risk factor, infants under 9 months old with 2 risk factors, and
infants under 15 months old with 3 risk factors. CONCLUSIONS: This study found
that prophylaxis with palivizumab is a cost-effective strategy for preterm children
compared with no prophylaxis and has different cost-effectiveness according to
the risk factors because of the influence on the risk of RSV hospitalization. There-
fore, it is reasonable to recommend the use of palivizumab for preterm infants in
subgroup with cost-effectiveness considering the risk factors.
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OBJECTIVES: To calculate the direct medical costs associated with HCV health
states by eliciting expert opinion. METHODS: Portuguese-specific annual direct
medical costs of HCV health states were estimated based on a national expert panel
with 8 clinicians experienced in HCV treatment at the national level. We adopted a
two-stage modified Delphi technique: First, experts independently answered ques-
tions concerning the resource use associated with each HCV-related health state.
Secondly, a consensus meeting was held where experts were encouraged to revise
their earlier answers after the panel discussion. The annual cost for each health
state of HCV disease was thereafter obtained by multiplying unit costs with the
consensus scores for each resource use. Unitary costs were obtained through na-
tional official sources. Fibrosis (F0-F3), compensated cirrhosis (CC), decompensated
cirrhosis (DC), hepatocellular carcinoma (HCC) and liver transplantation were set
as the different HCV health states with relevance for clinical and economic
research. RESULTS: Estimated annual costs per HCV health state were the follow-
ing: fibrosis (F0-F3) was €580, in advanced liver disease, CC was €1,156, whereas DC
was €8,222 for the first year and €9,085 for subsequent years. For HCC first year, the
annual cost was €20,749, whilst €19,088 for subsequent years. For liver transplant,
first year cost was €112,072, while for subsequent years it was €7,558. The consid-
erable difference between the costs associated with the first and subsequent years
is due to the transplant procedure being the cost driver for this health state.
CONCLUSIONS:Overall Cost of illness associated with HCV infection is substantial
in Portugal and increases throughout the liver disease health states. Strategies
aiming to treat HCV infection have the potential to decrease the disease progres-
sion and subsequent total costs associated with HCV-related liver disease. The
results from our research highlight this point and may support cost-effectiveness
analysis in the evaluation of those strategies.
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OBJECTIVES: The excessive and often unnecessary prescription of antibiotics and
the resulting increase in antibiotic resistance poses a serious medical problem. The
analysis provides data for assessing a health insurance company’s strategies aim-
ing to optimize antibiotic prescribing due to a quick C-reactive protein testing.
METHODS: Within a period of 22 months (January 2009 – October 2010), in a pop-
ulation sample of 365 690 insured persons from Slovakia, a connection was studied
between availability of a quick C-reactive protein testing as a service furnished by
medical care providers and a final cost of antibiotic treatment. A health insurance
fund provided data for this analysis. RESULTS: Higher consumption of antibiotics
can be linked to higher resistance to antibiotics. On the other hand this linkage is
not linear. In the analysis, the average expenditure per 1 patient at the level of 1.12
€ can be seen within GPs, where a quick C-reactive protein testing is available. On
the other hand, the average expenditure per 1 patient at the level of 1.35 € can be
seen within GPs, where a quick C-reactive protein testing is not available. The
average expenditure per 1 pediatric patient at the level of 1.64 € can be seen within
pediatric medicine, where a quick C-reactive protein testing is available. However,
the average expenditure per 1 pediatric patient at the level of 2.33 € can be seen
within pediatric medicine, where a quick C-reactive protein testing is not available.
Based on the analysis, we can finalised that in the case of an appropriate use of
C-reactive protein testing with the monitored sample of 365 690 insured persons
within the above mentioned period of 22 months, financial resources in a total
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